Antigen-specific Immune Tolerance is a fascinating aspect of the immune system, where the body learns to recognize and tolerate specific antigens, rather than mounting an immune response against them. This process is crucial for maintaining immune homeostasis and preventing harmful autoimmune reactions. In the context of vaccines, inducing antigen-specific immune tolerance holds great promise for treating autoimmune diseases, allergies, and transplant rejection. By modulating the immune response to specific antigens, vaccines can reprogram the immune system to tolerate self-antigens or harmless environmental antigens, while still maintaining the ability to mount protective responses against pathogens.
One approach to inducing antigen-specific immune tolerance is through the administration of tolerogenic vaccines. These vaccines contain antigens coupled with immune-modulating agents, such as anti-inflammatory cytokines or regulatory T cell-inducing compounds, which promote the generation of regulatory T cells (Tregs). Tregs play a key role in suppressing immune responses and maintaining tolerance to self-antigens. Another strategy involves the use of antigen-coupled nanoparticles or liposomes, which deliver antigens to antigen-presenting cells in a tolerogenic manner. These nanoparticles are designed to mimic the natural presentation of antigens in a non-inflammatory context, leading to the induction of antigen-specific tolerance.
In addition to vaccines, other approaches to inducing antigen-specific immune tolerance include oral tolerance induction, where antigens are administered orally to induce immune tolerance in the gut-associated lymphoid tissue, and antigen-specific immunotherapy, where small doses of antigen are administered over time to desensitize the immune system to allergens.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States